PAVmed Inc.

Stage 4 · Declining · week 25

As of Oct 22, 2026, PAVmed is in Stage 4, the downtrend phase, now in week 25 (since Apr 29, 2026). It closed at $2.05, 84.7% below its 52-week high and below its 200-day average, which is falling.

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. More about the company

$2.05

-2.15% today

$16.4M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PAVM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 56w

S4 17w

S4 41w

S4 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 56w → S1 10w → S4 17w → S1 9w → S4 41w → S1 8w → S4 25w current

Total tracked: 166 weeks across 7 stage runs.

PAVM among Medical Devices115th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…115	PAVMPAVmed Inc.	Stage 4 · wk 25	9	−48.6%

vs 52W High

-84.7%

$2.05 lo$13.44 hi

84.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 25

1w13w26w

Week 25, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-69.6%

200 DMA: $6.75 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.51x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-48.6%

-56.8%

-77.6%

YTD

-72.0%

-85.8%

Scan Membership

Breakout Watch

Latest: 2021-02-05

4 appearances in last 60 days. First seen: 2019-05-10.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 25 · Vol 0.51x

2026-10-21S4

Wk 25 · Vol 0.10x

2026-10-20S4

Wk 25 · Vol 0.17x

2026-10-19S4

Wk 24 · Vol 0.85x

2026-10-16S4

Wk 24 · Vol 0.36x

2026-10-15S4

Wk 24 · Vol 0.24x

2026-10-14S4

Wk 24 · Vol 0.18x

2026-10-13S4

Wk 24 · Vol 0.09x

2026-10-12S4

Wk 23 · Vol 0.24x

2026-10-09S4

Wk 23 · Vol 0.35x

2026-10-08S4

Wk 23 · Vol 0.11x

2026-10-07S4

Wk 23 · Vol 0.81x

Moving averages & range

50 DMA

$3.93

200 DMA

$6.75

52W High

$13.44

52W Low

$2.05

5D Low

$2.05

Resistance levels (recent highs)

20d High

$3.85

60d High

$5.50

120d High

$8.13

250d High

$13.44

Next resistance

+87.6%

to 20d High

ROE

-64.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

PAVmed: quick answers

What stage is PAVmed in?

As of Oct 22, 2026, PAVmed (PAVM) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 29, 2026 and is in week 25. What the four stages mean

Is PAVmed in an uptrend?

No. PAVmed is in a Stage 4 downtrend. It trades 69.6% below its 200-day average, which is falling.

How far is PAVmed from its 52-week high?

PAVmed closed at $2.05 on Oct 22, 2026, 84.7% below its 52-week high of $13.44. Its 52-week low is $2.05.

How has PAVmed performed over the past year?

As of Oct 22, 2026, PAVmed is down 85.8% over the past year and down 72.0% so far in 2026.

Which sector and industry is PAVmed in?

PAVmed is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.